Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Smoldering myeloma treatment landscape & MRD negativity

Annemiek Broyl • 5 Oct 2018
ESH MM 2018
Multiple Myeloma
GEM-CESAR QuiRedex

The best chance to acheive measurable residual disease (MRD) negativity is to treat in the smoldering stage of multiple myeloma (MM), as discussed here by Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands. Dr Broyl covers what the data indicate for the treatment of this population. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Annemiek Broyl

2:33
Treatment options for high-risk myeloma
Annemiek Broyl • 5 Oct 2018
1:56
How do we define a 'cure' in myeloma?
Annemiek Broyl • 6 Oct 2018

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals